Table 9 Univariate and multivariate cox regression analysis of HECW1 expression classifier and clinical characteristics with overall survival and progression-free survival in the validation cohort (n = 150) (1:1 ratio)

Age (≥60y vs < 60y)

1.037 (0.480–2.244)

0.926

0.978 (0.455–2.101)

0.955

Gender (Male vs Female)

0.729 (0.296–1.796)

0.492

1.117 (0.510–2.450)

0.782

WHO/ISUP Grading (III-IV vs I-II)

3.954 (1.873–8.345)

< 0.001

1.568 (0.657–3.745)

0.311

3.783 (1.832–7.811)

< 0.001

1.530 (0.673–3.478)

0.31

TNM stage (III-IV vs I-II)

9.069 (4.307–19.096)

< 0.001

3.832 (1.437–10.223)

0.007

7.319 (3.550–15.093)

< 0.001

2.503 (1.055–5.940)

0.037

SSIGN (≥5 vs 1–4)

7.223 (2.727–19.136)

< 0.001

5.953 (1.773–19.982)

0.004

15.156 (5.370–42.772)

< 0.001

9.803 (2.993–32.113)

< 0.001

HECW1 (High vs Low)

19.480 (5.883–64.500)

< 0.001

7.483 (1.897–29.514)

0.004

64.549 (8.782–474.440)

< 0.001

31.602 (3.989–250.386)

0.001